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There is an increasing burden of responsibility for
intensivists to optimize donation potential after the
declaration of brain death in patients with catastrophic
brain injury. Best practice for donor management, if
present, has been formed on low quality and mainly
observational studies or consensus. In particular,
research into the use of corticosteroids has shown
varied benefit. The specific and limited results of the
CORTICOME study are less important than the
systematic methodology and the development of
rigour in the study of deceased organ donation.
Donor management would benefit from continued
systematic analysis of current literature, understanding
of the physiologic basis for therapy, and further
prospective controlled trials. Worldwide collaboration
partnerships and funding are needed to optimize the
management of deceased organ donation.ent survival, and graft survival [5]. Studies have shownOrgan donation continues to save lives. There is an
increasing burden of responsibility for intensivists to
optimize donation potential after the declaration of
brain death in patients with catastrophic brain injury.
Until recently, organ donor management has been con-
sidered a low priority. As such, rigorous research to
guide improved organ procurement and graft survival
has been limited. Pinsard and colleagues [1] have com-
pleted a prospective multi-centre study showing the
benefits of low-dose corticosteroids after brain death.
Best practice for donor management, if present, has
mostly been formed on low quality and mainly observa-
tional studies or consensus [2]. It is more evident that the* Correspondence: sdhanani@cheo.on.ca
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donor management goals is significant [3]. But, benefits
and outcomes for individual interventions have been un-
clear. As a result, focus on donor management and the
uptake of best practices in the ICU have been difficult.
The systematic approach to research in organ donation
management needs to continue with further collaboration
and financial support.
Until now, research into the use of corticosteroids has
shown varied benefit. The overall quality of studies has
been poor with few randomized controlled studies and
mostly observational reports with limited patients and
high potential for confounding factors. Most of these
studies included other hormonal therapies rather than
corticosteroids alone [4]. A recent systematic review of
the use of corticosteroids in the management of brain
dead donors highlighted the low quality and conflicting
evidence when identifying outcomes of donor haemo-
dynamics and oxygenation, organ procurement, recipi-
increased lung utilization with high dose corticosteroids
and hormonal therapy [6] while other research has
shown minimal negative effects with use of corticoste-
roids in this group [7]. A large prospective study evalu-
ating the specific effect of corticosteroids was deemed
to be warranted.
Pinsard and colleagues should be commended for
accomplishing the challenging task of conducting a pro-
spective multi-centre study involving 259 subjects in
order to identify the benefits of low-dose corticosteroids
after brain death. The authors found that the need for
norepinephrine was reduced [1]. Although no benefits
were seen on transplantation or graft survival, the re-
duced dose and duration of vasopressor use may be a
clinically significant but limited outcome for intensivists
and transplant teams.
Though hypothesized, the mechanism for reduced dose
and duration of vasopressors with low dose hydrocorti-
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shock [8], perhaps as a result of increasing cardiac and
vascular sensitivity to catecholamines. Future adoption of
best practice in donor management needs to be guided
with a deeper understanding of biologic mechanisms and
effective interventions. The physiology for organ systems
failure after brain death is complex and multifactorial. For
example, the documented pro-inflammatory environ-
ment in the potential donor [9] has yet to translate into
antiflammatory therapies that improve graft function.
Optimization of the donor with multimodal approaches
including hormonal therapy need to be individualized
and based on our increasing knowledge of physiology
during the dying process.
Current donor management studies often suffer from
paradigm challenges. Traditional ICU interventional studies
aim to improve organ function and meaningful outcomes
in the patient receiving those interventions. Meanwhile,
donor management studies seek to improve organ function
in situ of another patient, the transplant recipient. Numer-
ous uncontrollable variables independent of donor manage-
ment impact on transplant outcomes (transplant logistics,
surgical procurement, preservation, storage, immuno-
suppressive therapies, recipient conditions, and so on).
While improving transplant outcomes is clearly the
most important goal, it may not be the most scientific-
ally valid outcome. The scientific question should first
assess whether a specific strategy improves organ func-
tion in the brain-dead donor themselves, and then sec-
ond, assess whether improved donor organ function
leads to increased organ utilization and transplant graft
survival. Outcomes analysis should change from trad-
itional graft survival to specific physiologic goal-directed
targets relevant at the bedside of the donor. We would
propose that physiologic outcomes and end organ func-
tion, such as haemodynamics, cardiac ejection fraction,
oxygenation status, hepatic markers, and renal function,
need to be prospectively measured to identify specific ben-
efits of specific donor management therapies.Conclusion
The systematic approach to research in organ donation
management is evolving slowly and is long overdue. The
current work on the use of corticosteroids is an example.
The specific and limited results of the CORTICOME
study are less important than the systematic methodology
and the development of rigour in the study of deceased
organ donation. The same must be accomplished for other
therapies, individually and combined, including fluid man-
agement and haemodynamic supports. In the future, more
aggressive, novel, and multimodal interventions need to
be studied. Collaboration with transplant research, to
identify immunomodulating targets in potential donors,should be pursued. Donor management would benefit
from continued systematic analysis of current literature,
understanding of the physiologic basis for therapy, and
further prospective controlled trials.
For deceased organ donation research to flourish, na-
tional and worldwide collaborative partnerships need to
be formed as they were developed for other disease
states such as sepsis and traumatic brain injury. Appro-
priate funding must also be committed to prospective
research and initiatives. The basis of this collaboration
and support would effectively eliminate the 'art' and cre-
ate a new scientific rigour to the management of de-
ceased organ donation. With increased collaboration
and funding, the potential to save lives through opti-
mized organ donation, given the multi-patient recipient
impact of each donor, may be greater than that seen
with other recent initiatives.
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